Ambrosia Biosciences Inc. ("Ambrosia"), today announced preclinical data supporting its small molecule GLP-1 receptor agonist ...

HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates ...

Cellogen develops next‑generation therapies to treat cancers and blood disorders at a fraction of the price of existing solutions globally The startup's lead product, XenCAR-T, targets both CD19 and ...

The combined solutions support characterization capabilities for antibodies that cannot be achieved using standalone methods.

Bio‑Techne Corporation, a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in ...

In a groundbreaking new study, researchers modified a human hookworm and got it to manufacture and secrete functional human ...

Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 ...

Targeted protein degradation (TPD) therapeutics seek to harness this intrinsic quality control machinery to selectively ...

Amyloid is increasingly ceding ground in Alzheimer’s disease R&D to new approaches targeting inflammation, immune processes, ...

Today, before a scientist ever picks up a pipette, much of the early work can happen with the help of computers. this shift ...

Vivid Sydney wraps its 16th year on Saturday 13 June, and the festival has saved a suspicious amount of its best material for ...